Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Fennec Pharmaceuticals to ...

Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a ...

Q4 2024 Earnings Call Transcript March 10, 2025 Fennec Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is ...

Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. The stock was recently down 10% to $6.20 and is down about 2% this year.

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Fennec Pharmaceuticals (FENC – Research Report) today. The company’s shares ...

Reports Q4 revenue $7.93M, consensus $16.42M. “2024 marked the beginning of a foundational transformation for Fennec (FENC), setting the stage ...

Fennec Pharmaceuticals Inc (FENC) reports a 40% revenue increase and successful PEDMARK launches in Europe, while navigating competitive challenges and operational expenses.

FENNEC PHARMACEUTICALS ($FENC) posted quarterly earnings results on Monday, March 10th. The company reported earnings of -$0.06 per share, missing estimates of $0.17 ...

Good morning ladies and gentlemen, and welcome to Fennec Pharmaceuticals fourth quarter and full year 2024 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's ...

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. At this time, all participants are in a ...